Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor

被引：0
|
作者：
Moshe C. Ornstein
Laura S. Wood
机构：
[1] Cleveland Clinic,Hematology and Medical Oncology
[2] Cleveland Clinic,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adverse event; Axitinib; Combination; First-line; Immune checkpoint inhibitor; Renal cell carcinoma; Therapy management;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3599 / 3609
页数：10
相关论文
共 50 条
  • [41] Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma REPLY
    Rini, Brian I.
    Powles, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (26): : 2582 - 2582
  • [42] Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations
    Narang, Arshit
    Gebrael, Georges
    Jo, Yeonjung
    Thomas, Vinay Mathew
    Li, Haoran
    Fortuna, Gliceida Galarza
    Sayegh, Nicolas
    Tandar, Clara
    Tripathi, Nishita
    Chigarira, Beverly
    Srivastava, Ayana
    Chehade, Chadi Hage
    Nordblad, Blake
    Maughan, Benjamin L.
    Agarwal, Neeraj
    Swami, Umang
    KIDNEY CANCER, 2024, 8 (01) : 135 - 142
  • [43] Impact of pretreatment body mass index on clinical outcomes in patients with metastatic renal cell carcinoma receiving first-line immune checkpoint inhibitor-based therapy: A systematic review and meta-analysis
    Lee, Kunwoo
    Yu, Jiwoong
    Song, Wan
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Kang, Minyong
    INVESTIGATIVE AND CLINICAL UROLOGY, 2024, 65 (05) : 423 - 434
  • [44] Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
    Huang, T.
    Jiang, L.
    Wei, W.
    Zheng, X.
    Zhang, Z.
    Guo, S.
    Han, H.
    Cai, X.
    Zhou, F.
    Dong, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1559 - S1560
  • [45] Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).
    Bakouny, Ziad
    Abou Alaiwi, Sarah
    Nassar, Amin
    Steinharter, John A.
    Wei, Xiao X.
    McGregor, Bradley Alexander
    Harshman, Lauren Christine
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [46] Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
    Koie, Takuya
    Ohyama, Chikara
    Yoneyama, Takahiro
    Yamamoto, Hayato
    Imai, Atsushi
    Hatakeyama, Shingo
    Hashimoto, Yasuhiro
    Yoneyama, Tohru
    Tobisawa, Yuki
    Mori, Kazuyuki
    BMC UROLOGY, 2015, 15
  • [47] Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
    Takuya Koie
    Chikara Ohyama
    Takahiro Yoneyama
    Hayato Yamamoto
    Atsushi Imai
    Shingo Hatakeyama
    Yasuhiro Hashimoto
    Tohru Yoneyama
    Yuki Tobisawa
    Kazuyuki Mori
    BMC Urology, 15
  • [48] First-Line Therapy of Metastatic Renal Cell Carcinoma - Update 2009
    Miller, Kurt
    ONKOLOGIE, 2010, 33 : 5 - 9
  • [49] Radical shifts in the first-line management of metastatic renal cell carcinoma
    Ornstein, Moshe C.
    Rini, Brian I.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (02) : 71 - 72
  • [50] Radical shifts in the first-line management of metastatic renal cell carcinoma
    Moshe C. Ornstein
    Brian I. Rini
    Nature Reviews Clinical Oncology, 2019, 16 : 71 - 72
12345